eicosapentaenoic acid ethyl ester has been researched along with Coronary Disease in 3 studies
Coronary Disease: An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To examine the effect of purified eicosapentaenoic acid ethyl ester (EPA) on the fibrinolytic capacity in patients with stable CAD and arteriosclerosis obliterans (ASO)." | 3.69 | Effect of purified eicosapentaenoate ethyl ester on fibrinolytic capacity in patients with stable coronary artery disease and lower extremity ischaemia. ( Kaiga, K; Miyao, Y; Ogawa, H; Sakamoto, T; Tanae, H; Tsuruta, K; Yasue, H, 1996) |
| "Hypercholesterolemia affects over 34 million adults in the United States and is a major cause of coronary heart disease (CHD)." | 1.39 | New therapeutic alternatives for the management of dyslipidemia. ( Cassagnol, M; Ezzo, D; Patel, PN, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cassagnol, M | 1 |
| Ezzo, D | 1 |
| Patel, PN | 1 |
| Caffrey, MK | 1 |
| Tsuruta, K | 1 |
| Ogawa, H | 1 |
| Yasue, H | 1 |
| Sakamoto, T | 1 |
| Miyao, Y | 1 |
| Tanae, H | 1 |
| Kaiga, K | 1 |
3 other studies available for eicosapentaenoic acid ethyl ester and Coronary Disease
| Article | Year |
|---|---|
New therapeutic alternatives for the management of dyslipidemia.
Topics: Adult; Anticholesteremic Agents; Benzimidazoles; Coronary Disease; Drug Approval; Eicosapentaenoic A | 2013 |
To treat or not to treat? Questions, controversies in prevention.
Topics: Cardiology; Cardiovascular Diseases; Congresses as Topic; Coronary Disease; Decision Making; Diabete | 2014 |
Effect of purified eicosapentaenoate ethyl ester on fibrinolytic capacity in patients with stable coronary artery disease and lower extremity ischaemia.
Topics: Administration, Oral; Adult; Aged; Antigens; Arteriosclerosis Obliterans; Blood Cell Count; Blood Gl | 1996 |